3-9-05

Express Mail No. EV 452 774 934 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plication of:

Kougiouris et al.

Confirmation No.:

4229

Serial No.:

10/690,343

Art Unit:

October 20, 2003

Examiner: To be assigned

For:

Filed:

SYSTEM AND METHOD **ENABLING MULTIPLE**

Attorney Docket No.:

2171

11389-036-999

PROCESSES TO EFFICIENTLY

LOG EVENTS

CAM No.: 902782-999035

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1.

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

Enclos	ures accompanying this Information Disclosure Statement are:
1a.	A list of all patents, publications, applications, or other information submitted for consideration by the office.
1b.	A legible copy of:
	☐ Each foreign patent;
	☐ Each publication or that portion which caused it to be listed on the PTO-1449;
	For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
	all other information or portion which caused it to be listed on the PTO-1449.
1c.	An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.
1d.	Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.
le.	☑ In accordance with 1276 OG 55, since this application was filed after June 30, 2003, this Information Disclosure Statement is filed without copies of References, which are U.S. patent documents, U.S. patent applications filed after June 30, 2003 and international applications that have entered the national stage under 35 U.S.C. § 371 after June 30, 2003

2.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b): Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
		Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
		⊠ Before the mailing of the first Office action on the merits;
		Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.
		(Check either Item 3a or 3b)
	3a.	☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
	3b.	☐ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
		enclosed
		to be charged to Jones Day Deposit Account No. 50-3013.
		(Item 3b to be checked if any reference known for more than 3 months)
4.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.
	The Ce	ertification Statement in Item 5 below is applicable.
		The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is: enclosed.
		to be charged to Jones Day Deposit Account No. 50-3013
5.		Certification Statement (applicable if Item 3a or Item 4 is checked)
		(Check either Item 5a or 5b)
	5a.	In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	5b.	Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
	5c.	Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign

patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

6.	\boxtimes	This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).
		(Check appropriate Items 6a, 6b and/or 6c)
	6a.	A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
	6b.	Copies of publications listed on Form PTO-1449 from prior application Serial No. 09/439,374, filed on November 15, 1999, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
	6c.	Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.
7.	\boxtimes	This is a Supplemental Information Disclosure Statement. (Check Item 7a)
	7a.	∑ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on October 20, 2003.
8.		The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 50-3013.
9.		No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).
		Respectfully submitted,
Date:	March	7, 2005
Date.	March	For: Ognian V. Shento 38,051
		By: Michael Fainberg 50,441
		JÓNES DAY
		222 East 41st Street (Reg. No.)

New York, New York 10017

(212) 326-3939

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO. 11389-036-999 CAM 902782-999035 APPLICATION NO

10/690,343

APPLICANT

Kougiouris et al.


FILING DATE
October 20, 2003

GROUP 2171

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
	A01	6,826,696	11/30/2004	Chawla et al.	713	201	
	A02	6,449,598	09/10/2002	Green et al.	705	2	
	A03	6,401,072	06/2002	Haudenschild et al.	705	3	
	A04	6,385,611	05/07/2002	Cardona, Carlos	707	6	
	A05	6,362,836 B1	03/26/2002	Shaw et al.	345	744	1-18-
	A06	6,334,778	01/01/2002	Brown	273	429	
	A07	6,347,374	02/12/2002	Drake et al.	713	200	
	A08	6,2952,796	09/18/2001	Drucker et al.	707	4	
	A09	6,263,330	07/17/2001	Bessette, Luc	707	4	
	A10	6,253,228 B1	06/26/2001	Ferris et al.	709	203	
	A11	6,189,036	02/13/2001	Kao	709	229	
	A12	6,178,416 B1	01/23/2001	Thompson et al.	707	3	
	A13	6,167,523	12/26/000	Strong	713	201	
	A14	6,141,759	10/31/2000	Braddy	713	201	
	A15	6,112,183	08/29/2000	Swanson et al.	705	2	
	A18	6,092,196	07/18/2000	Reiche	713	200	
	A17	6,073,163	06/6/000	Clark et al.	709	203	
	A18	6,073,106	06/6/2000	Rosen et al.	709	3	
	A19	6,070,160	05//30/2000	Geary	707	4	_
<u>-</u>	A20	6,031,818	02/29/2000	Lo et al.	370	216	
	A21	6,018,619	01/25/2000	Allard et al.	709	224	
	A22	6,006,269	12/21/1999	Phaal	709	227	
	A23	5,996,715	10/12/1999	Sweeney et al.	707	203	
	A24	5,978,842	11/02/1999	Noble et al.	709	218	
	A25	5,974,412	10/26/1999	Hazlehurst et al.	707	3	
	A26	5,967,789	10/19/1999	Segel et al.	434	236	
	A27	5,960,403	09/28/1999	Brown	705	2	
	A28	5,953,704	09/14/1999	McIlroy et al.	705	2	
	A29	5,915,240	06/22/1999	Karpf	705	2	
	A30	5,905,884	05/18/1999	Williams	709	227	
	A31	5,903,889	0511//1999	De la Huerga et al.	707	3	
	A32	5,867,821	02/02/1999	Ballantyne et al.	705	2	
	A33	5,857,190	01/05/1999	Brown, Matt	707	10	
	A34	5,862,327	01/19/1999	Kwang et al.	709	203	

A35 5,848,397 12/8/1998 Marsh et al. 705 14 A36 5,845,255 12/1998 Mayaud 705 3 A37 5,841,970 11/24/1998 Tabuki 713 201 A38 5,832,488 11/1998 Eberhardt 707 10 A39 5,827,180 10/1998 Goodman 600 300 A40 5,809,476 09-1998 Ryan, John Kevin 705 2 A41 5,815,665 09/29/1998 Teper et al. 709 229 A42 5,790,785 08/04/1998 Klug et al. 713 202 A43 5,772,585 06/1998 Lavin et al. 600 300 A44 5,664,207 09/1997 Crumpler et al. 715 505 A45 5,664,109 09/1997 Johnson et al. 705 2 A46 5,629,981 05/1997 Nertikar 713 168 A47 5,588,148 12/24/1996 Landis et al. 705 3 A49 5,560,008 09/24/	
A37 5,841,970 11/24/1998 Tabuki 713 201 A38 5,832,488 11/1998 Eberhardt 707 10 A39 5,827,180 10/1998 Goodman 600 300 A40 5,809,476 09-1998 Ryan, John Kevin 705 2 A41 5,815,665 09/29/1998 Teper et al. 709 229 A42 5,790,785 08/04/1998 Klug et al. 713 202 A43 5,772,585 06/1998 Lavin et al. 600 300 A44 5,664,207 09/1997 Crumpler et al. 715 505 A45 5,664,109 09/1997 Johnson et al. 705 2 A46 5,629,981 05/1997 Nerlikar 713 168 A47 5.588,148 12/24/1996 Landis et al. 705 3 A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A38 5,832,488 11/1998 Eberhardt 707 10 A39 5,827,180 10/1998 Goodman 600 300 A40 5,809,476 09-1998 Ryan, John Kevin 705 2 A41 5,815,665 09/29/1998 Teper et al. 709 229 A42 5,790,785 08/04/1998 Klug et al. 713 202 A43 5,772,585 06/1998 Lavin et al. 600 300 A44 5,664,207 09/1997 Crumpler et al. 715 505 A45 5,664,109 09/1997 Johnson et al. 705 2 A46 5,629,981 05/1997 Nerlikar 713 168 A47 5.588,148 12/24/1996 Landis et al. 707 1 A48 5,572,422 11/1996 Nematbakhsh et al. 705 3 A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A39 5,827,180 10/1998 Goodman 600 300 A40 5,809,476 09-1998 Ryan, John Kevin 705 2 A41 5,815,665 09/29/1998 Teper et al. 709 229 A42 5,790,785 08/04/1998 Klug et al. 713 202 A43 5,772,585 06/1998 Lavin et al. 600 300 A44 5,664,207 09/1997 Crumpler et al. 715 505 A45 5,664,109 09/1997 Johnson et al. 705 2 A46 5,629,981 05/1997 Nerlikar 713 168 A47 5.588,148 12/24/1996 Landis et al. 707 1 A48 5,572,422 11/1996 Nematbakhsh et al. 705 3 A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A40 5,809,476 09-1998 Ryan, John Kevin 705 2 A41 5,815,665 09/29/1998 Teper et al. 709 229 A42 5,790,785 08/04/1998 Klug et al. 713 202 A43 5,772,585 06/1998 Lavin et al. 600 300 A44 5,664,207 09/1997 Crumpler et al. 715 505 A45 5,664,109 09/1997 Johnson et al. 705 2 A46 5,629,981 05/1997 Nerlikar 713 168 A47 5.588,148 12/24/1996 Landis et al. 707 1 A48 5,572,422 11/1996 Nematbakhsh et al. 705 3 A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A41 5,815,665 09/29/1998 Teper et al. 709 229 A42 5,790,785 08/04/1998 Klug et al. 713 202 A43 5,772,585 06/1998 Lavin et al. 600 300 A44 5,664,207 09/1997 Crumpler et al. 715 505 A45 5,664,109 09/1997 Johnson et al. 705 2 A46 5,629,981 05/1997 Nerlikar 713 168 A47 5.588,148 12/24/1996 Landis et al. 707 1 A48 5,572,422 11/1996 Nematbakhsh et al. 705 3 A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A42 5,790,785 08/04/1998 Klug et al. 713 202 A43 5,772,585 06/1998 Lavin et al. 600 300 A44 5,664,207 09/1997 Crumpler et al. 715 505 A45 5,664,109 09/1997 Johnson et al. 705 2 A46 5,629,981 05/1997 Nerlikar 713 168 A47 5.588,148 12/24/1996 Landis et al. 707 1 A48 5,572,422 11/1996 Nematbakhsh et al. 705 3 A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A43 5,772,585 06/1998 Lavin et al. 600 300 A44 5,664,207 09/1997 Crumpler et al. 715 505 A45 5,664,109 09/1997 Johnson et al. 705 2 A46 5,629,981 05/1997 Nerlikar 713 168 A47 5.588,148 12/24/1996 Landis et al. 707 1 A48 5,572,422 11/1996 Nematbakhsh et al. 705 3 A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A44 5,664,207 09/1997 Crumpler et al. 715 505 A45 5,664,109 09/1997 Johnson et al. 705 2 A46 5,629,981 05/1997 Nerlikar 713 168 A47 5.588,148 12/24/1996 Landis et al. 707 1 A48 5,572,422 11/1996 Nematbakhsh et al. 705 3 A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A44 5,664,207 09/1997 Crumpler et al. 715 505 A45 5,664,109 09/1997 Johnson et al. 705 2 A46 5,629,981 05/1997 Nerlikar 713 168 A47 5.588,148 12/24/1996 Landis et al. 707 1 A48 5,572,422 11/1996 Nematbakhsh et al. 705 3 A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A46 5,629,981 05/1997 Nerlikar 713 168 A47 5.588,148 12/24/1996 Landis et al. 707 1 A48 5,572,422 11/1996 Nematbakhsh et al. 705 3 A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A47 5.588,148 12/24/1996 Landis et al. 707 1 A48 5,572,422 11/1996 Nematbakhsh et al. 705 3 A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A48 5,572,422 11/1996 Nematbakhsh et al. 705 3 A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A49 5,560,008 09/24/1996 Johnson et al. 713 201 A50 5,559,888 09/1996 Jain et al. 380 25	
A50 5,559,888 09/1996 Jain et al. 380 25	
A51 5 550 995 0011006 De 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
A51 5,559,885 09/1996 Drexler et al. 235 380	
A52 5,550,971 8/1996 Brunner et al. 395 161	
A53 5,465,082 11/1995 Chaco 340 825.49	
A54 5,327,341 07/1994 Whalen et al. 705 3	
A55 5,325,294 06/1994 Keene 705 3	
A56 5,301,246 04/1994 Archibald et al. 379 142.06	
A57 5,301,105 04/1994 Cummings, Jr. 705 2	
A58 5,241,671 08/1663 Reed et al. 707 104.1	
A59 5,150,409 09/1992 Elsner 713 177	
A60 5,491,800 02/1996 Goldsmith et al. 709 221	
A61 5,430,875 07/1995 Ma, Yin-Shur D. 719 318	
A62 5,251,152 10/1993 Notess, Peter C. 709 224	
A63 4,984,272 01/1991 McIlroy et al. 713 202	
A64 4,960,982 10/1990 Takahira 235 382	
A65 4,949,251 08/1990 Griffen et al. 714 20	
A66 4,916,611 04/1990 Doyle, Jr. et al. 705 2	
A67 4,882,474 11/1989 Anderl et al. 235 380	
A68 4,858,121 08/1989 Barber et al. 705 2	
A69 4,868,376 09/1989 Lessin et al. 235 492	
A70 4,812,994 03/1989 Taylor et al. 705 410	
A71 4,315,309 02/1982 Coli 705 3	



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.